This content is machine translated Antiphospholipid syndrome Preferably anticoagulate with VKA or heparin Antiphospholipid syndrome (APS) is an acquired thrombophilia and is associated with a high risk of venous, arterial or microvascular thrombosis. In APS with thrombotic manifestations, lifelong anticoagulation is generally indicated.…
View Post 7 min This content is machine translated VTE PREDICT risk score Estimation of benefits and harms of extended anticoagulation The decision to discontinue or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging because individual risks for recurrence and bleeding are heterogeneous. Therefore, one study investigated the…
View Post 4 min This content is machine translated Pulmonary embolism Anticoagulate hemodynamically unstable patients even on suspicion Patients with pulmonary embolism require anticoagulation for a period of at least three months. Before starting therapy, several considerations must be addressed: Which anticoagulant is the most appropriate for this…
View Post 12 min This content is machine translated Venous thromboembolism Risks associated with hormone therapy Venous thromboembolism (VTE) is the third most common cardiovascular disease in Central Europe. They manifest as deep vein thrombosis in about two-thirds of cases and with symptoms of pulmonary embolism… CME-Test
View Post 10 min This content is machine translated Anticoagulation from the perspective of internal medicine Foundations for an individualized “Choosing wisely”. DOAK are at least equal to standard therapy with VKA in non-valvular VCF and venous thromboembolism in terms of safety and efficacy. The intracranial bleeding risk is halved. Consequently, they…
View Post 2 min This content is machine translated Developments in angiology With VTE and PAVK, something is always going on Angiology has again seen great strides in development in recent years, mainly involving the most important and common vascular diseases, peripheral arterial disease, and venous thromboembolism. The new generation of…
